(8E,12E,14E)-3,6,16,21-tetrahydroxy-6,10,12,16,20-pentamethyl-7-((4-propylhomopiperazin-1-yl)carbonyl)oxy-18,19-epoxytricosa-8,12,14-trien-11-olide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (8E,12E,14E)-3,6,16,21-tetrahydroxy-6,10,12,16,20-pentamethyl-7-((4-propylhomopiperazin-1-yl)carbonyl)oxy-18,19-epoxytricosa-8,12,14-trien-11-olide
• 英文别名: [(4E)-7,10-dihydroxy-2-[(2E,4E)-6-hydroxy-7-[3-(3-hydroxypentan-2-yl)oxiran-2-yl]-6-methylhepta-2,4-dien-2-yl]-3,7-dimethyl-12-oxo-1-oxacyclododec-4-en-6-yl] 4-propyl-1,4-diazepane-1-carboxylate
• 化学式: C₃₇H₆₂N₂O₉
• 分子量: 678.907
• InChiKey: LVMJGWBWHSQQFT-GCEXOZPRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  48
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  153
• 氢给体数：
  4
• 氢受体数：
  10

文献信息

• Novel physiologically active substances
  申请人：Kotake Yoshihiko

  公开号：US20060009439A1

  公开（公告）日：2006-01-12

  The present invention relates to a compound represented by the formula (I): (wherein, R 3 , R 6 , R 7 and R 21 are the same as or different from one another and each represents a hydroxyl group etc.), a pharmacologically acceptable salt thereof or a hydrate of them. The compound (I) of the present invention suppresses angiogenesis, in particular, suppresses VEGF production in a hypoxic condition and is useful as a therapeutic agent for treating solid cancer.

  本发明涉及一种由以下式（I）表示的化合物：（其中，R3、R6、R7和R21彼此相同或不同，且每个代表羟基等），其药学上可接受的盐或水合物。本发明的化合物（I）抑制血管生成，特别是在缺氧条件下抑制VEGF的产生，并且可用作治疗实体癌的治疗剂。
• NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES
  申请人：KOTAKE Yoshihiko

  公开号：US20080255146A1

  公开（公告）日：2008-10-16

  The present invention relates to a compound represented by the formula (I): (wherein, R 3 , R 6 , R 7 and R 21 are the same as or different from one another and each represents a hydroxyl group etc.), a pharmacologically acceptable salt thereof or a hydrate of them. The compound (I) of the present invention suppresses angiogenesis, in particular, suppresses VEGF production in a hypoxic condition and is useful as a therapeutic agent for treating solid cancer.

  本发明涉及一种由式(I)表示的化合物：（其中，R3、R6、R7和R21相同或不同，每个代表羟基等），其药学上可接受的盐或水合物。本发明的化合物(I)抑制血管生成，特别是在低氧条件下抑制VEGF的产生，并且可用作治疗实体癌的治疗剂。
• NOVEL PHYSIOLGICALLY ACTIVE SUBSTANCES
  申请人：MERCIAN CORPORATION

  公开号：EP1508570A1

  公开（公告）日：2005-02-23

  The present invention relates to a compound represented by the formula (I): (wherein, R3, R6, R7 and R21 are the same as or different from one another and each represents a hydroxyl group etc.), a pharmacologically acceptable salt thereof or a hydrate of them. The compound (I) of the present invention suppresses angiogenesis, in particular, suppresses VEGF production in a hypoxic condition and is useful as a therapeutic agent for treating solid cancer.

  本发明涉及由式(I)代表的化合物： (其中，R3、R6、R7 和 R21 彼此相同或不同，且各自代表羟基等）、其药理学上可接受的盐或它们的水合物。本发明的化合物(I)可抑制血管生成，特别是在缺氧条件下抑制血管内皮生长因子的产生，可作为治疗实体癌的治疗剂。
• METHOD FOR EXAMINATION OF ACTION OF ANTI-CANCER AGENT UTILIZING SPLICING DEFECT AS MEASURE
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP2136209A1

  公开（公告）日：2009-12-23

  An object of the present invention is to provide a method, a probe, a primer, an antibody, a reagent, and a kit for assaying an action of a pladienolide derivative to a living subject. According to the present invention, there is provided a method for assaying an action of the pladienolide derivative using splicing defect as an index.

  本发明的目的是提供一种方法、一种探针、一种引物、一种抗体、一种试剂和一种试剂盒，用于检测一种 pladienolide 衍生物对活体的作用。根据本发明，提供了一种以剪接缺陷为指标来检测 pladienolide 衍生物作用的方法。
• METHOD FOR ASSAYING ACTION OF ANTITUMOR AGENT USING SPLICING DEFECTS AS INDEX
  申请人：Mizui Yoshiharu

  公开号：US20100021918A1

  公开（公告）日：2010-01-28

  An object of the present invention is to provide a method, a probe, a primer, an antibody, a reagent, and a kit for assaying an action of a pladienolide derivative to a living subject. According to the present invention, there is provided a method for assaying an action of the pladienolide derivative using splicing defect as an index.